1 2302 132 EPIGENETIC REGULATION OF CANCER STEM CELL MARKER CD133 BY TRANSFORMING GROWTH FACTOR-BETA. HEPATOCELLULAR CARCINOMA (HCC) IS THE THIRD LEADING CAUSE OF CANCER MORTALITY WORLDWIDE. CD133, A TRANSMEMBRANE GLYCOPROTEIN, IS AN IMPORTANT CELL SURFACE MARKER FOR BOTH STEM CELLS AND CANCER STEM CELLS IN VARIOUS TISSUES INCLUDING LIVER. CD133 EXPRESSION HAS BEEN RECENTLY LINKED TO POOR PROGNOSIS IN HCC PATIENTS. CD133+ LIVER CANCER CELLS ARE CHARACTERIZED BY RESISTANCE TO CHEMOTHERAPY, SELF-RENEWAL, MULTILINEAGE POTENTIAL, INCREASED COLONY FORMATION, AND IN VIVO CANCER INITIATION AT LIMITED DILUTION. RECENT STUDIES DEMONSTRATE THAT CD133 EXPRESSION IS REGULATED BY DNA METHYLATION. IN THIS STUDY, WE EXPLORED THE ROLE OF TRANSFORMING GROWTH FACTOR BETA (TGFBETA), A MULTIFUNCTIONAL CYTOKINE THAT PLAYS A CRITICAL ROLE IN CHRONIC LIVER INJURY, IN THE REGULATION OF CD133 EXPRESSION. TGFBETA1 IS CAPABLE OF UP-REGULATING CD133 EXPRESSION SPECIFICALLY WITHIN THE HUH7 HCC CELL LINE IN A TIME- AND DOSE-DEPENDENT MANNER. MOST IMPORTANT, TGFBETA1-INDUCED CD133+ HUH7 CELLS DEMONSTRATE INCREASED TUMOR INITIATION IN VIVO. FORCED EXPRESSION OF INHIBITORY SMADS, INCLUDING SMAD6 AND SMAD7, ATTENUATED TGFBETA1-INDUCED CD133 EXPRESSION. WITHIN CD133- HUH7 CELLS, TGFBETA1 STIMULATION INHIBITED THE EXPRESSION OF DNA METHYLTRANSFERASES (DNMT) 1 AND DNMT3BETA, WHICH ARE CRITICAL IN THE MAINTENANCE OF REGIONAL DNA METHYLATION, AND GLOBAL DNMT ACTIVITY IN CD133- HUH7 CELLS WAS INHIBITED BY TGFBETA1. DNMT3BETA INHIBITION BY TGFBETA1 WAS PARTIALLY RESCUED WITH OVEREXPRESSION OF INHIBITORY SMADS. LASTLY, TGFBETA1 TREATMENT LED TO SIGNIFICANT DEMETHYLATION IN CD133 PROMOTER-1 IN CD133- HUH7 CELLS. CONCLUSION: TGFBETA1 IS ABLE TO REGULATE CD133 EXPRESSION THROUGH INHIBITION OF DNMT1 AND DNMT3BETA EXPRESSION AND SUBSEQUENT DEMETHYLATION OF PROMOTER-1. TGFBETA1-INDUCED CD133+ HUH7 CELLS ARE TUMORIGENIC. THE MECHANISM BY WHICH TGFBETA INDUCES CD133 EXPRESSION IS PARTIALLY DEPENDENT ON THE SMADS PATHWAY. 2010 2 2334 33 EPIGENETIC REGULATION OF INFLAMMATORY CYTOKINE-INDUCED EPITHELIAL-TO-MESENCHYMAL CELL TRANSITION AND CANCER STEM CELL GENERATION. THE NEOPLASTIC TRANSFORMATION OF NORMAL TO METASTATIC CANCER CELLS IS A COMPLEX MULTISTEP PROCESS INVOLVING THE PROGRESSIVE ACCUMULATION OF INTERACTING GENETIC AND EPIGENETIC CHANGES THAT ALTER GENE FUNCTION AND AFFECT CELL PHYSIOLOGY AND HOMEOSTASIS. EPIGENETIC CHANGES INCLUDING DNA METHYLATION, HISTONE MODIFICATIONS AND CHANGES IN NONCODING RNA EXPRESSION, AND DEREGULATION OF EPIGENETIC PROCESSES CAN ALTER GENE EXPRESSION DURING THE MULTISTEP PROCESS OF CARCINOGENESIS. CANCER PROGRESSION AND METASTASIS THROUGH AN 'INVASION-METASTASIS CASCADE' INVOLVING AN EPITHELIAL-TO-MESENCHYMAL CELL TRANSITION (EMT), THE GENERATION OF CANCER STEM CELLS (CSCS), INVASION OF ADJACENT TISSUES, AND DISSEMINATION ARE FUELED BY INFLAMMATION, WHICH IS CONSIDERED A HALLMARK OF CANCER. CHRONIC INFLAMMATION IS GENERATED BY INFLAMMATORY CYTOKINES SECRETED BY THE TUMOR AND THE TUMOR-ASSOCIATED CELLS WITHIN THE TUMOR MICROENVIRONMENT. INFLAMMATORY CYTOKINE SIGNALING INITIATES SIGNALING PATHWAYS LEADING TO THE ACTIVATION OF MASTER TRANSCRIPTION FACTORS (TFS) SUCH AS SMADS, STAT3, AND NF-KAPPAB. MOREOVER, THE SAME INFLAMMATORY RESPONSES ALSO ACTIVATE EMT-INDUCING TF (EMT-TF) FAMILIES SUCH AS SNAIL, TWIST, AND ZEB, AND EPIGENETIC REGULATORS INCLUDING DNA AND HISTONE MODIFYING ENZYMES AND MICORNAS, THROUGH COMPLEX INTERCONNECTED POSITIVE AND NEGATIVE FEEDBACK LOOPS TO REGULATE EMT AND CSC GENERATION. HERE, WE REVIEW THE MOLECULAR REGULATORY FEEDBACK LOOPS AND NETWORKS INVOLVED IN INFLAMMATORY CYTOKINE-INDUCED EMT AND CSC GENERATION. 2019 3 6235 27 THE M(6)A DEMETHYLASE FTO PROMOTES RENAL EPITHELIAL-MESENCHYMAL TRANSITION BY REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5. BACKGROUND: RENAL INTERSTITIAL FIBROSIS (RIF) IS THE MAIN PATHOLOGICAL CHANGE OF A VARIETY OF CHRONIC KIDNEY DISEASES (CKD). EPIGENETIC MODIFICATIONS OF FIBROSIS-PRONE GENES REGULATE RIF PROGRESSION. THIS STUDY AIMED TO INVESTIGATE LONG NON-CODING RNA (LNCRNA) N6-METHYLADENOSINE (M(6)A) MODIFICATION AND ITS ROLE IN REGULATING RIF PROGRESSION. METHODS: UNILATERAL URETERAL OCCLUSION (UUO) WAS EMPLOYED TO CONSTRUCT THE RIF IN VIVO MODEL; AND TGF-BETA1-TREATED HK-2 AND HKC-8 CELLS WERE USED FOR IN VITRO EXPERIMENTS. THE MRNA AND PROTEIN EXPRESSIONS WERE ASSESSED USING QRT-PCR AND WESTERN BLOT. THE PROLIFERATION AND MIGRATION WERE EVALUATED BY EDU ASSAY AND TRANSWELL ASSAY, RESPECTIVELY. IN ADDITION, LEVELS OF INFLAMMATORY CYTOKINES WERE DETERMINED BY ELISA ASSAY AND QRT-PCR. MOREOVER, LNCRNA GAS5 M(6)A LEVEL WAS DETECTED USING ME-RIP ASSAY. HE AND MASSON STAINING WERE EMPLOYED TO EVALUATE FIBROTIC LESIONS OF THE KIDNEY. RESULTS: FTO EXPRESSION WAS ELEVATED IN HK-2 AND HKC-8 CELLS AFTER TGF-BETA1 TREATMENT AND MOUSE KIDNEY TISSUE FOLLOWING UUO, AND LNCRNA GAS5 WAS DOWNREGULATED. LNCRNA GAS5 OVEREXPRESSION OR FTO SILENCING SUPPRESSED TGF-BETA1-INDUCED THE INCREASE OF EMT-RELATED PROTEINS (VIMENTIN, SNAIL AND N-CADHERIN) AND INFLAMMATORY CYTOKINES (IL-6, IL-1BETA AND TNF-ALPHA) LEVELS IN HK-2 CELLS. FTO SUPPRESSED LNCRNA GAS5 EXPRESSION BY REDUCING THE M6A MODIFICATION OF LNCRNA GAS5. ADDITIONALLY, FTO KNOCKDOWN COULD SUPPRESS EMT PROCESS AND INFLAMMATION RESPONSE INDUCED BY TGF-BETA1 AND UUO IN VITRO AND IN VIVO. AS EXPECTED, FTO KNOCKDOWN ABROGATED THE PROMOTION EFFECTS OF LNCRNA GAS5 SILENCING ON TGF-BETA1-INDUCED EMT PROCESS AND INFLAMMATION RESPONSE IN HK-2 AND HKC-8 CELLS. CONCLUSION: FTO PROMOTED EMT PROCESS AND INFLAMMATION RESPONSE THROUGH REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5. 2022 4 1700 48 DYNAMIC EXPRESSION OF ZNF382 AND ITS TUMOR-SUPPRESSOR ROLE IN HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOGENESIS. HEPATITIS B VIRUS (HBV) INFECTION IS THE PRIMARY CAUSE OF HEPATOCELLULAR CARCINOMA (HCC). ZINC-FINGER PROTEIN 382 (ZNF382), WHICH BELONGS TO ZINC-FINGER PROTEIN FAMILY, HAS BEEN DOCUMENTED TO BE DOWNREGULATED IN CERTAIN TYPES OF CANCER. HOWEVER, ITS ROLE IN HCC REMAINS LARGELY UNKNOWN. IN THIS STUDY, WE DEMONSTRATED THAT ZNF382 EXPRESSION WAS SIGNIFICANTLY ELEVATED IN HBV-INFECTED LIVER CIRRHOSIS TISSUES RELATIVE TO HBV-NEGATIVE NORMAL LIVER TISSUES AT PROTEIN LEVELS, BUT NOT AT MRNA LEVELS, AND WAS POSITIVELY CORRELATED WITH THE LEVELS OF HBV DNA AND HEPATITIS B VIRUS X PROTEIN (HBX). FURTHER STUDIES REVEALED THAT ZNF382 WAS A TARGET OF MIR-6867, AND HBX PROMOTED THE TRANSLATION OF ZNF382 DURING HBV CHRONIC INFECTION THROUGH ERK-MEDIATED MIR-6867 INHIBITION. IN ADDITION, OUR DATA SHOWED THAT ZNF382 WAS FREQUENTLY DOWNREGULATED BY PROMOTER METHYLATION IN HBV-RELATED HCCS RELATIVE TO HBV-INFECTED LIVER CIRRHOSIS TISSUES, AND DECREASED EXPRESSION OF ZNF382 WAS STRONGLY CORRELATED WITH POOR SURVIVAL IN EARLY-STAGE HCC PATIENTS. FUNCTIONAL STUDIES DEMONSTRATED THAT ZNF382 WAS A POTENT TUMOR SUPPRESSOR IN HCC CELLS THROUGH INHIBITING CELL PROLIFERATION, COLONY FORMATION, MIGRATION, INVASION, AND TUMORIGENIC POTENTIAL IN NUDE MICE, AND INDUCING CELL APOPTOSIS. MECHANISTICALLY, ZNF382 EXERTED ITS TUMOR-SUPPRESSOR FUNCTIONS IN HCC THROUGH TRANSCRIPTIONALLY REPRESSING ITS DOWNSTREAM TARGETS SUCH AS FOS PROTO-ONCOGENE (FOS), JUN PROTO-ONCOGENE (JUN), DISHEVELED SEGMENT POLARITY PROTEIN 2 (DVL2), AND FRIZZLED CLASS RECEPTOR 1 (FZD1), THEREBY IMPAIRING THE ACTIVITIES OF ACTIVATING PROTEIN 1 (AP-1) AND WNT/BETA-CATENIN PATHWAYS AND ACTIVATING P53 SIGNALING. ALTOGETHER, OUR DATA SHOW THAT ZNF382 ACTS AS A TUMOR SUPPRESSOR, AND IS CO-REGULATED BY HBX AND EPIGENETIC MECHANISM IN HBV-RELATED HEPATOCELLULAR CARCINOGENESIS. 2019 5 699 34 BROMODOMAIN PROTEIN 4 IS A KEY MOLECULAR DRIVER OF TGFBETA1-INDUCED HEPATIC STELLATE CELL ACTIVATION. LIVER FIBROSIS IS CHARACTERIZED BY THE EXCESSIVE DEPOSITION OF EXTRACELLULAR MATRIX IN LIVER. CHRONIC LIVER INJURY INDUCES THE ACTIVATION OF HEPATIC STELLATE CELL (HSCS), A KEY STEP IN LIVER FIBROGENESIS. THE ACTIVATED HSC IS THE PRIMARY SOURCE OF ECM AND CONTRIBUTES SIGNIFICANTLY TO LIVER FIBROSIS. TGFBETA1 IS THE MOST POTENT PRO-FIBROTIC CYTOKINE. BROMODOMAIN PROTEIN 4 (BRD4), AN EPIGENETIC READER OF HISTONE ACETYLATION MARKS, WAS CRUCIAL FOR PROFIBROTIC GENE EXPRESSION IN HSCS. THE PRESENT STUDY AIMED TO INVESTIGATE THE ROLES OF BRD4 IN TGFBETA1-DEPENDENT HSC ACTIVATION AND LIVER FIBROSIS, FOCUSING ON TGFBETA1-INDUCED ALTERATIONS OF THE LEVELS OF THE FIBROTIC-RELATED IMPORTANT PROTEINS IN HSCS BY EMPLOYING THE HETEROZYGOUS TGFBETA1 KNOCKOUT MICE AND BRD4 KNOCKDOWN IN VIVO AND IN VITRO. RESULTS REVEALED THAT BRD4 PROTEIN LEVEL WAS SIGNIFICANTLY UPREGULATED BY TGFBETA1 AND BRD4 KNOCKDOWN REDUCED TGFBETA1-INDUCED HSC ACTIVATION AND LIVER FIBROSIS. BRD4 WAS REQUIRED FOR THE INFLUENCES OF TGFBETA1 ON PDGFBETA RECEPTOR AND ON THE PATHWAYS OF SMAD3, STAT3, AND AKT. BRD4 ALSO MEDIATED TGFBETA1-INDUCED INCREASES IN HISTONE ACETYLTRANSFERASE P300, THE PIVOTAL PRO-INFLAMMATORY NFKB P65, AND TISSUE INHIBITOR OF METALLOPROTEINASE 1 WHEREAS BRD4 REDUCED CASPASE-3 PROTEIN LEVELS IN HSCS DURING LIVER INJURY, INDEPENDENT OF TGFBETA1. FURTHER EXPERIMENTS INDICATED THE INTERACTION BETWEEN TGFBETA1-INDUCED BRD4 AND NFKB P65 IN HSCS AND IN LIVER OF TAA-INDUCED LIVER INJURY. HUMAN CIRRHOTIC LIVERS WERE DEMONSTRATED A PARALLEL INCREASE IN THE PROTEIN LEVELS OF BRD4 AND NFKB P65 IN HSCS. THIS STUDY REVEALED THAT BRD4 WAS A KEY MOLECULAR DRIVER OF TGFBETA1-INDUCED HSC ACTIVATION AND LIVER FIBROSIS. 2023 6 767 32 CD24 MEDIATES GASTRIC CARCINOGENESIS AND PROMOTES GASTRIC CANCER PROGRESSION VIA STAT3 ACTIVATION. THE DEVELOPMENT OF GASTRIC CANCER (GC) IS A COMPLEX MULTISTEP PROCESS, INCLUDING NUMEROUS GENETIC AND EPIGENETIC CHANGES. CD24 IS ASSOCIATED WITH ENHANCED INVASIVENESS OF GC AND A POOR PROGNOSIS. HOWEVER, THE MECHANISM BY WHICH CD24 INDUCES GC PROGRESSION REMAINS POORLY CHARACTERIZED. HERE, WE FOUND THAT THE EXPRESSION OF CD24 GRADUALLY INCREASED IN SAMPLES OF NORMAL GASTRIC MUCOSA, NON-ATROPHIC CHRONIC GASTRITIS, CHRONIC ATROPHIC GASTRITIS (CAG), CAG WITH INTESTINAL METAPLASIA, DYSPLASIA AND GC. MOREOVER, THE KNOCKDOWN OF CD24 INDUCED SIGNIFICANT LEVELS OF APOPTOSIS IN GC CELLS VIA THE MITOCHONDRIAL APOPTOTIC PATHWAY. CD24 MAY ALSO PROMOTE CELLULAR INVASION AND REGULATE THE EXPRESSION OF E-CADHERIN, FIBRONECTIN AND VITAMIN D RECEPTOR IN GC CELLS. THE ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) MAY MEDIATE CD24-INDUCED GC SURVIVAL AND INVASION IN VITRO. FURTHERMORE, CD24-INDUCED GC PROGRESSION AND STAT3 ACTIVATION COULD ALSO BE DETECTED IN VIVO AND IN CLINICAL GC TISSUES SAMPLES. TAKEN TOGETHER, OUR RESULTS INDICATE THAT CD24 MEDIATES GASTRIC CARCINOGENESIS AND MAY PROMOTE GC PROGRESSION BY SUPPRESSING APOPTOSIS AND PROMOTING INVASION, WITH THE ACTIVATION OF STAT3 PLAYING A CRITICAL ROLE. 2014 7 1730 21 DYSREGULATION OF STEM CELL SIGNALING NETWORK DUE TO GERMLINE MUTATION, SNP, HELICOBACTER PYLORI INFECTION, EPIGENETIC CHANGE AND GENETIC ALTERATION IN GASTRIC CANCER. GENETIC FACTORS, HELICOBACTER PYLORI INFECTION, SALT OVER-UPTAKE, DECREASED VEGETABLE/FRUIT CONSUMPTION, SMOKING, AND METABOLIC SYNDROME ARE RISK FACTORS OF HUMAN GASTRIC CANCER. GERMLINE MUTATIONS OF CDH1 GENE, AND SNPS OF PTPN11 (SHP2), TLR4, IL1B, TNFA, BMP6, GDF15 AND RUNX3 GENES ARE ASSOCIATED WITH GASTRIC CANCER. HELICOBACTER PYLORI ACTIVATES CAGA-SHP2-ERK AND PEPTIDOGLYCAN-NOD1-NFKAPPAB SIGNALING CASCADES IN GASTRIC EPITHELIAL CELLS USING TYPE IV SECRETION SYSTEM, AND ALSO TRAF6-MAP3K7-NFKAPPAB AND TRAF6-MAP3K7-AP-1 SIGNALING CASCADES IN EPITHELIAL AND IMMUNE CELLS THROUGH LIPOPOLYSACCHARIDE RECOGNITION BY TLR2 OR TLR4. IL-1BETA, IL-6, IL-8, TNFALPHA AND IFNGAMMA ARE ELEVATED IN GASTRIC MUCOSA WITH HELICOBACTER PYLORI INFECTION. IL-6 AND TNFALPHA INDUCE UPREGULATION OF WNT5A AND WNT10B, RESPECTIVELY. WNT SIGNALS ARE TRANSDUCED TO BETA-CATENIN-TCF/LEF, RHOA, JNK, PKC, NFAT, AND NLK SIGNALING CASCADES. WNT-BETA-CATENIN-TCF/LEF SIGNALING INDUCES UPREGULATION OF MYC, CCND1, WISP1, FGF20, JAG1 AND DKK1 GENES. NOTCH SIGNALS ARE TRANSDUCED TO CSL-NICD-MAML AND NFKAPPAB SIGNALING CASCADES. FGF SIGNALS ARE TRANSDUCED TO ERK, PI3K-AKT, PKC, AND NFAT SIGNALING CASCADES. HELICOBACTER PYLORI INFECTION INDUCES SHH UPREGULATION IN PARIETAL CELL LINEAGE, WHILE BMP SIGNALS INDUCE IHH UPREGULATION IN PIT CELL LINEAGE. HEDGEHOG SIGNALS INDUCE UPREGULATION OF GLI1, PTCH1, CCND2, FOXL1, JAG2 AND SFRP1 GENES. JAG1 AND JAG2 ACTIVATE NOTCH SIGNALING, WHILE DKK1 AND SFRP1 INHIBIT WNT SIGNALING. STEM CELL SIGNALING NETWORK, CONSISTING OF WNT, NOTCH, FGF, HEDGEHOG AND BMP SIGNALING PATHWAYS, IS ACTIVATED DURING CHRONIC HELICOBACTER PYLORI INFECTION. EPIGENETIC SILENCING OF SFRP1 GENE OCCURS IN THE EARLIER STAGE OF CARCINOGENESIS IN THE STOMACH, WHILE AMPLIFICATION AND OVEREXPRESSION OF FGFR2 GENE IN THE LATER STAGE. DYSREGULATION OF THE STEM CELL SIGNALING NETWORK DUE TO THE ACCUMULATION OF GERMLINE MUTATION, SNP, HELICOBACTER PYLORI INFECTION, EPIGENETIC CHANGE AND GENETIC ALTERATION GIVES RISE TO GASTRIC CANCER. SNP TYPING AND CUSTOM-MADE MICROARRAY ANALYSES ON GENES ENCODING STEM CELL SIGNALING MOLECULES COULD BE UTILIZED FOR THE PERSONALIZED MEDICINE. 2007 8 1632 38 DNMTS ARE INVOLVED IN TGF-BETA1-INDUCED EPITHELIAL-MESENCHYMAL TRANSITIONS IN AIRWAY EPITHELIAL CELLS. CHRONIC RHINOSINUSITIS (CRS) PATHOGENESIS IS CLOSELY RELATED TO TISSUE REMODELING, INCLUDING EPITHELIAL-MESENCHYMAL TRANSITION (EMT). EPIGENETIC MECHANISMS PLAY KEY ROLES IN EMT. DNA METHYLATION, MEDIATED BY DNA METHYLTRANSFERASES (DNMTS), IS AN EPIGENETIC MARKER THAT IS CRITICAL TO EMT. THE GOAL OF THIS STUDY WAS TO DETERMINE WHETHER DNMTS WERE INVOLVED IN TGF-BETA1-INDUCED EMT AND ELUCIDATE THE UNDERLYING MECHANISMS IN NASAL EPITHELIAL CELLS AND AIR-LIQUID INTERFACE CULTURES. GLOBAL DNA METHYLATION AND DNMT ACTIVITY WERE QUANTIFIED. DNMT EXPRESSION WAS MEASURED USING REAL-TIME PCR (QRT-PCR) IN HUMAN CRS TISSUES. MRNA AND PROTEIN LEVELS OF DNMTS, E-CADHERIN, VIMENTIN, ALPHA-SMA, AND FIBRONECTIN WERE DETERMINED USING RT-PCR AND WESTERN BLOTTING, RESPECTIVELY. DNMT1, DNMT3A, AND DNMT3B GENE EXPRESSION WERE KNOCKED DOWN USING SIRNA TRANSFECTION. MAPK PHOSPHORYLATION AND EMT-RELATED TRANSCRIPTION FACTOR LEVELS WERE DETERMINED USING WESTERN BLOTTING. SIGNALING PATHWAYS WERE ANALYZED USING SPECIFIC INHIBITORS OF MAPK. WE DEMONSTRATED THESE DATA IN PRIMARY NASAL EPITHELIAL CELLS AND AIR-LIQUID INTERFACE CULTURES. GLOBAL DNA METHYLATION, DNMT ACTIVITY, AND DNMT EXPRESSION INCREASED IN CRS TISSUES. DNMT EXPRESSION WAS POSITIVELY CORRELATED WITH LUND-MCKAY CT SCORES. TGF-BETA1 DOSE-DEPENDENTLY INDUCED DNMT EXPRESSION. FURTHER, 5-AZA INHIBITED TGF-BETA1-INDUCED DNMT, SNAIL, AND SLUG EXPRESSION RELATED TO EMT, AS WELL AS P38 AND JNK PHOSPHORYLATION IN A549 CELLS AND TGF-BETA1-INDUCED DNMT EXPRESSION AND EMT IN PRIMARY NASAL EPITHELIAL CELLS AND AIR-LIQUID INTERFACE CULTURES. TGF-BETA1-INDUCED DNMT EXPRESSION LEADS TO DNA METHYLATION AND EMT VIA P38, JNK, SNAIL, AND SLUG SIGNALING PATHWAYS. INHIBITION OF DNMT SUPPRESSED THE EMT PROCESS AND THEREFORE IS POTENTIALLY A CRS THERAPEUTIC STRATEGY. 2022 9 866 35 CHRONIC ACTIVATION OF MUC1-C IN WOUND REPAIR PROMOTES PROGRESSION TO CANCER STEM CELLS. THE MUCIN 1 (MUC1) GENE EMERGED IN MAMMALS TO AFFORD PROTECTION OF BARRIER EPITHELIAL TISSUES FROM THE EXTERNAL ENVIRONMENT. MUC1 ENCODES A TRANSMEMBRANE C-TERMINAL (MUC1-C) SUBUNIT THAT IS ACTIVATED BY LOSS OF HOMEOSTASIS AND INDUCES INFLAMMATORY, PROLIFERATIVE, AND REMODELING PATHWAYS ASSOCIATED WITH WOUND REPAIR. AS A CONSEQUENCE, CHRONIC ACTIVATION OF MUC1-C PROMOTES LINEAGE PLASTICITY, EPIGENETIC REPROGRAMMING, AND CARCINOGENESIS. IN DRIVING CANCER PROGRESSION, MUC1-C IS IMPORTED INTO THE NUCLEUS, WHERE IT INDUCES NF-KAPPAB INFLAMMATORY SIGNALING AND THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). MUC1-C REPRESSES GENE EXPRESSION BY ACTIVATING (I) DNA METHYLTRANSFERASE 1 (DNMT1) AND DNMT3B, (II) POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) AND PRC2, AND (III) THE NUCLEOSOME REMODELING AND DEACETYLASE (NURD) COMPLEX. PRC1/2-MEDIATED GENE REPRESSION IS COUNTERACTED BY THE SWI/SNF CHROMATIN REMODELING COMPLEXES. MUC1-C ACTIVATES THE SWI/SNF BAF AND PBAF COMPLEXES IN CANCER STEM CELL (CSC) MODELS WITH THE INDUCTION OF GENOME-WIDE DIFFERENTIALLY ACCESSIBLE REGIONS AND EXPRESSED GENES. MUC1-C REGULATES CHROMATIN ACCESSIBILITY OF ENHANCER-LIKE SIGNATURES IN ASSOCIATION WITH THE INDUCTION OF THE YAMANAKA PLURIPOTENCY FACTORS AND RECRUITMENT OF JUN AND BAF, WHICH PROMOTE INCREASES IN HISTONE ACTIVATION MARKS AND OPENING OF CHROMATIN. THESE AND OTHER FINDINGS DESCRIBED IN THIS REVIEW HAVE UNCOVERED A PIVOTAL ROLE FOR MUC1-C IN INTEGRATING LINEAGE PLASTICITY AND EPIGENETIC REPROGRAMMING, WHICH ARE TRANSIENT IN WOUND REPAIR AND SUSTAINED IN PROMOTING CSC PROGRESSION. 2022 10 2425 29 EPIGENETIC SILENCING OF IRF1 DYSREGULATES TYPE III INTERFERON RESPONSES TO RESPIRATORY VIRUS INFECTION IN EPITHELIAL TO MESENCHYMAL TRANSITION. CHRONIC OXIDATIVE INJURY PRODUCED BY AIRWAY DISEASE TRIGGERS A TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA)-MEDIATED EPIGENETIC REPROGRAMMING KNOWN AS THE EPITHELIAL-MESENCHYMAL TRANSITION (EMT). WE OBSERVE THAT EMT SILENCES PROTECTIVE MUCOSAL INTERFERON (IFN)-I AND III PRODUCTION ASSOCIATED WITH ENHANCED RHINOVIRUS (RV) AND RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION. MESENCHYMAL TRANSITIONED CELLS ARE DEFECTIVE IN INDUCIBLE INTERFERON REGULATORY FACTOR 1 (IRF1) EXPRESSION BY OCCLUDING RELA AND IRF3 ACCESS TO THE PROMOTER. IRF1 IS NECESSARY FOR THE EXPRESSION OF TYPE III IFNS (IFNLS 1 AND 2/3). INDUCED BY THE EMT, ZINC FINGER E-BOX BINDING HOMEOBOX 1 (ZEB1) BINDS AND SILENCES IRF1. ECTOPIC ZEB1 IS SUFFICIENT FOR IRF1 SILENCING, WHEREAS ZEB1 KNOCKDOWN PARTIALLY RESTORES IRF1-IFNL UPREGULATION. ZEB1 SILENCES IRF1 THROUGH THE CATALYTIC ACTIVITY OF THE ENHANCER OF ZESTE 2 POLYCOMB REPRESSIVE COMPLEX 2 SUBUNIT (EZH2), FORMING REPRESSIVE H3K27(ME3) MARKS. WE OBSERVE THAT IRF1 EXPRESSION IS MEDIATED BY ZEB1 DE-REPRESSION, AND OUR STUDY DEMONSTRATES HOW AIRWAY REMODELLING/FIBROSIS IS ASSOCIATED WITH A DEFECTIVE MUCOSAL ANTIVIRAL RESPONSE THROUGH ZEB1-INITIATED EPIGENETIC SILENCING. 2017 11 5795 28 STAT3 INDUCTION OF MIR-146B FORMS A FEEDBACK LOOP TO INHIBIT THE NF-KAPPAB TO IL-6 SIGNALING AXIS AND STAT3-DRIVEN CANCER PHENOTYPES. INTERLEUKIN-6 (IL-6)-MEDIATED ACTIVATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) IS A MECHANISM BY WHICH CHRONIC INFLAMMATION CAN CONTRIBUTE TO CANCER AND IS A COMMON ONCOGENIC EVENT. WE DISCOVERED A PATHWAY, THE LOSS OF WHICH IS ASSOCIATED WITH PERSISTENT STAT3 ACTIVATION IN HUMAN CANCER. WE FOUND THAT THE GENE ENCODING THE TUMOR SUPPRESSOR MICRORNA MIR-146B IS A DIRECT STAT3 TARGET GENE, AND ITS EXPRESSION WAS INCREASED IN NORMAL BREAST EPITHELIAL CELLS BUT DECREASED IN TUMOR CELLS. METHYLATION OF THE MIR-146B PROMOTER, WHICH INHIBITED STAT3-MEDIATED INDUCTION OF EXPRESSION, WAS INCREASED IN PRIMARY BREAST CANCERS. MOREOVER, WE FOUND THAT MIR-146B INHIBITED NUCLEAR FACTOR KAPPAB (NF-KAPPAB)-DEPENDENT PRODUCTION OF IL-6, SUBSEQUENT STAT3 ACTIVATION, AND IL-6/STAT3-DRIVEN MIGRATION AND INVASION IN BREAST CANCER CELLS, THEREBY ESTABLISHING A NEGATIVE FEEDBACK LOOP. IN ADDITION, HIGHER EXPRESSION OF MIR-146B WAS POSITIVELY CORRELATED WITH PATIENT SURVIVAL IN BREAST CANCER SUBTYPES WITH INCREASED IL6 EXPRESSION AND STAT3 PHOSPHORYLATION. OUR RESULTS IDENTIFY AN EPIGENETIC MECHANISM OF CROSSTALK BETWEEN STAT3 AND NF-KAPPAB RELEVANT TO CONSTITUTIVE STAT3 ACTIVATION IN MALIGNANCY AND THE ROLE OF INFLAMMATION IN ONCOGENESIS. 2014 12 6549 43 TRANSFORMING GROWTH FACTOR BETA INHIBITS MUC5AC EXPRESSION BY SMAD3/HDAC2 COMPLEX FORMATION AND NF-KAPPAB DEACETYLATION AT K310 IN NCI-H292 CELLS. AIRWAY MUCUS SECRETION IS AN ESSENTIAL INNATE IMMUNE RESPONSE FOR HOST PROTECTION. HOWEVER, OVERPRODUCTION AND HYPERSECRETION OF MUCUS, MAINLY COMPOSED OF THE GEL- FORMING MUC5AC PROTEIN, ARE SIGNIFICANT RISK FACTORS FOR PATIENTS WITH ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). THE TRANSFORMING GROWTH FACTOR BETA (TGFBETA) SIGNALING PATHWAY NEGATIVELY REGULATES MUC5AC EXPRESSION; HOWEVER, THE UNDERLYING MOLECULAR MECHANISM IS NOT FULLY UNDERSTOOD. HERE, WE SHOWED THAT TGFBETA SIGNIFICANTLY REDUCES THE EXPRESSION OF MUC5AC MRNA AND ITS PROTEIN IN NCI-H292 CELLS, A HUMAN MUCOEPIDERMOID CARCINOMA CELL LINE. THIS REDUCED MUC5AC EXPRESSION WAS RESTORED BY A TGFBETA RECEPTOR INHIBITOR (SB431542), BUT NOT BY THE INHIBITION OF NF-KAPPAB (BAY11-7082 OR TRIPTOLIDE) OR PI3K (LY294002) ACTIVITIES. TGFBETA-ACTIVATED SMAD3 DOSE-DEPENDENTLY BOUND TO MUC5AC PROMOTER. NOTABLY, TGFBETA-ACTIVATED SMAD3 RECRUITED HDAC2 AND FACILITATED NUCLEAR TRANSLOCATION OF HDAC2, THEREBY INDUCING THE DEACETYLATION OF NF-KAPPAB AT K310, WHICH IS ESSENTIAL FOR A REDUCTION IN NF-KAPPAB TRANSCRIPTIONAL ACTIVITY. BOTH TGFBETA-INDUCED NUCLEAR TRANSLOCATION OF SMAD3/HDAC2 AND DEACETYLATION OF NF-KAPPAB AT K310 WERE SUPPRESSED BY A SMAD3 INHIBITOR (SIS3). THESE RESULTS SUGGEST THAT THE TGFBETA-ACTIVATED SMAD3/HDAC2 COMPLEX IS AN ESSENTIAL NEGATIVE REGULATOR FOR MUC5AC EXPRESSION AND AN EPIGENETIC REGULATOR FOR NF-KAPPAB ACETYLATION. THEREFORE, THESE RESULTS COLLECTIVELY SUGGEST THAT MODULATION OF THE TGFBETA1/SMAD3/HDAC2/NF-KAPPAB PATHWAY AXIS CAN BE A PROMISING WAY TO IMPROVE LUNG FUNCTION AS A TREATMENT STRATEGY FOR ASTHMA AND COPD. 2021 13 5994 42 TGFBETA-INCURRED EPIGENETIC ABERRATIONS OF MIRNA AND DNA METHYLTRANSFERASE SUPPRESS KLOTHO AND POTENTIATE RENAL FIBROSIS. RENAL FIBROSIS IS A COMMON PATHOLOGICAL FEATURE OF CHRONIC KIDNEY DISEASES (CKD) AND ITS DEVELOPMENT AND PROGRESSION ARE SIGNIFICANTLY AFFECTED BY EPIGENETIC MODIFICATIONS SUCH AS ABERRANT MIRNA AND DNA METHYLATION. KLOTHO IS AN ANTI-AGING AND ANTI-FIBROTIC PROTEIN AND ITS EARLY DECLINE AFTER RENAL INJURY IS REPORTEDLY ASSOCIATED WITH ABERRANT DNA METHYLATION. HOWEVER, THE KEY UPSTREAM PATHOLOGICAL MEDIATORS AND THE MOLECULAR CASCADE LEADING TO EPIGENETIC KLOTHO SUPPRESSION ARE NOT EXCLUSIVELY ESTABLISHED. HERE WE INVESTIGATE THE EPIGENETIC MECHANISM OF KLOTHO DEFICIENCY AND ITS FUNCTIONAL RELEVANCE IN RENAL FIBROGENESIS. FIBROTIC KIDNEYS INDUCED BY UNILATERAL URETERAL OCCLUSION (UUO) DISPLAYED MARKED KLOTHO SUPPRESSION AND THE PROMOTER HYPERMETHYLATION. THESE ABNORMALITIES WERE LIKELY DUE TO DEREGULATED TRANSFORMING GROWTH FACTOR-BETA (TGFBETA) SINCE TGFBETA ALONE CAUSED THE SIMILAR EPIGENETIC ABERRATIONS IN CULTURED RENAL CELLS AND TGFBETA BLOCKADE PREVENTED THE ALTERATIONS IN UUO KIDNEY. FURTHER INVESTIGATION REVEALED THAT TGFBETA ENHANCED DNA METHYLTRANSFERASE (DNMT) 1 AND DNMT3A VIA INHIBITING MIR-152 AND MIR-30A IN BOTH RENAL CELLS AND FIBROTIC KIDNEYS. ACCORDINGLY THE BLOCKADE OF EITHER TGFBETA SIGNALING OR DNMT1/3A ACTIVITIES SIGNIFICANTLY RECOVERED THE KLOTHO LOSS AND ATTENUATED PRO-FIBROTIC PROTEIN EXPRESSION AND RENAL FIBROSIS. MOREOVER, KLOTHO KNOCKDOWN BY RNA INTERFERENCES ABOLISHED THE ANTI-FIBROTIC EFFECTS OF DNMT INHIBITION IN BOTH TGFBETA-TREATED RENAL CELL AND UUO KIDNEY, INDICATING THAT TGFBETA-MEDIATED MIR-152/30A INHIBITIONS, DNMT1/3A ABERRATIONS AND SUBSEQUENT KLOTHO LOSS CONSTITUTE A CRITICAL REGULATORY LOOP THAT ELIMINATES KLOTHO'S ANTI-FIBROTIC ACTIVITIES AND POTENTIATES RENAL FIBROGENESIS. THUS, OUR STUDY ELABORATES A NOVEL EPIGENETIC CASCADE OF RENAL FIBROGENESIS AND REVEALS THE POTENTIAL THERAPEUTIC TARGETS FOR TREATING THE RENAL FIBROSIS-ASSOCIATED KIDNEY DISEASES. 2017 14 234 37 ADDICTION OF CANCER STEM CELLS TO MUC1-C IN TRIPLE-NEGATIVE BREAST CANCER PROGRESSION. TRIPLE-NEGATIVE BREAST CANCER (TNBC) IS AN AGGRESSIVE MALIGNANCY WITH LIMITED TREATMENT OPTIONS. TNBC PROGRESSION IS ASSOCIATED WITH EXPANSION OF CANCER STEM CELLS (CSCS). FEW INSIGHTS ARE AVAILABLE REGARDING DRUGGABLE TARGETS THAT DRIVE THE TNBC CSC STATE. THIS REVIEW SUMMARIZES THE LITERATURE ON TNBC CSCS AND THE COMPELLING EVIDENCE THAT THEY ARE ADDICTED TO THE MUC1-C TRANSMEMBRANE PROTEIN. IN NORMAL EPITHELIA, MUC1-C IS ACTIVATED BY LOSS OF HOMEOSTASIS AND INDUCES REVERSIBLE WOUND-HEALING RESPONSES OF INFLAMMATION AND REPAIR. HOWEVER, IN SETTINGS OF CHRONIC INFLAMMATION, MUC1-C PROMOTES CARCINOGENESIS. MUC1-C INDUCES EMT, EPIGENETIC REPROGRAMMING AND CHROMATIN REMODELING IN TNBC CSCS, WHICH ARE DEPENDENT ON MUC1-C FOR SELF-RENEWAL AND TUMORIGENICITY. MUC1-C-INDUCED LINEAGE PLASTICITY IN TNBC CSCS CONFERS DNA DAMAGE RESISTANCE AND IMMUNE EVASION BY CHRONIC ACTIVATION OF INFLAMMATORY PATHWAYS AND GLOBAL CHANGES IN CHROMATIN ARCHITECTURE. OF THERAPEUTIC SIGNIFICANCE, AN ANTIBODY GENERATED AGAINST THE MUC1-C EXTRACELLULAR DOMAIN HAS BEEN ADVANCED IN A CLINICAL TRIAL OF ANTI-MUC1-C CAR T CELLS AND IN IND-ENABLING STUDIES FOR DEVELOPMENT AS AN ANTIBODY-DRUG CONJUGATE (ADC). AGENTS TARGETING THE MUC1-C CYTOPLASMIC DOMAIN HAVE ALSO ENTERED THE CLINIC AND ARE UNDERGOING FURTHER DEVELOPMENT AS CANDIDATES FOR ADVANCING TNBC TREATMENT. ELIMINATING TNBC CSCS WILL BE NECESSARY FOR CURING THIS RECALCITRANT CANCER AND MUC1-C REPRESENTS A PROMISING DRUGGABLE TARGET FOR ACHIEVING THAT GOAL. 2022 15 6232 33 THE LONG NONCODING RNA MEG3 REGULATES MYOBLAST PLASTICITY AND MUSCLE REGENERATION THROUGH EPITHELIAL-MESENCHYMAL TRANSITION. FORMATION OF SKELETAL MUSCLE IS AMONG THE MOST STRIKING EXAMPLES OF CELLULAR PLASTICITY IN ANIMAL TISSUE DEVELOPMENT, AND WHILE MUSCLE PROGENITOR CELLS ARE REPROGRAMMED BY EPITHELIAL-MESENCHYMAL TRANSITION (EMT) TO MIGRATE DURING EMBRYONIC DEVELOPMENT, THE REGULATION OF EMT IN POST-NATAL MYOGENESIS REMAINS POORLY UNDERSTOOD. HERE, WE DEMONSTRATE THAT THE LONG NONCODING RNA (LNCRNA) MEG3 REGULATES EMT IN MYOBLAST DIFFERENTIATION AND SKELETAL MUSCLE REGENERATION. CHRONIC INHIBITION OF MEG3 IN C2C12 MYOBLASTS INDUCED EMT, AND SUPPRESSED CELL STATE TRANSITIONS REQUIRED FOR DIFFERENTIATION. FURTHERMORE, ADENOVIRAL MEG3 KNOCKDOWN COMPROMISED MUSCLE REGENERATION, WHICH WAS ACCOMPANIED BY ABNORMAL MESENCHYMAL GENE EXPRESSION AND INTERSTITIAL CELL PROLIFERATION. TRANSCRIPTOMIC AND PATHWAY ANALYSES OF MEG3-DEPLETED C2C12 MYOBLASTS AND INJURED SKELETAL MUSCLE REVEALED A SIGNIFICANT DYSREGULATION OF EMT-RELATED GENES, AND IDENTIFIED TGFBETA AS A KEY UPSTREAM REGULATOR. IMPORTANTLY, INHIBITION OF TGFBETAR1 AND ITS DOWNSTREAM EFFECTORS, AND THE EMT TRANSCRIPTION FACTOR SNAI2, RESTORED MANY ASPECTS OF MYOGENIC DIFFERENTIATION IN MEG3-DEPLETED MYOBLASTS IN VITRO WE FURTHER DEMONSTRATE THAT REDUCTION OF MEG3-DEPENDENT EZH2 ACTIVITY RESULTS IN EPIGENETIC ALTERATIONS ASSOCIATED WITH TGFBETA ACTIVATION. THUS, MEG3 REGULATES MYOBLAST IDENTITY TO FACILITATE PROGRESSION INTO DIFFERENTIATION. 2021 16 6134 19 THE EPIGENETICALLY-REGULATED MIR-34A TARGETING C-SRC SUPPRESSES RAF/MEK/ERK SIGNALING PATHWAY IN K-562 CELLS. PREVIOUS REPORTS SHOW THAT MIR-34A SUPPRESSED K-562 CELL PROLIFERATION AND CONTRIBUTED TO MEGAKARYOCYTIC DIFFERENTIATION OF K-562 CELLS. HERE, WE REPORTED THAT MIR-34A, A TUMOR SUPPRESSOR GENE, IS DOWN-REGULATED IN THE K-562 CELLS AND CHRONIC MYELOID LEUKEMIA (CML) PATIENTS DUE TO ABERRANT DNA HYPERMETHYLATION. C-SRC IS A TARGET OF MIR-34A. RESTORING MIR-34A EXPRESSION RESULTED IN DOWN-REGULATION OF C-SRC AND PHOSPHORYLATED (TYR416) C-SRC PROTEIN IN K-562 CELLS, WHICH CONSEQUENTLY TRIGGERED SUPPRESSION OF THE RAF/MEK/ERK SIGNALING PATHWAY TO DECREASE CELL PROLIFERATION. 2017 17 3946 40 LNCRNA MALAT1 BINDS CHROMATIN REMODELING SUBUNIT BRG1 TO EPIGENETICALLY PROMOTE INFLAMMATION-RELATED HEPATOCELLULAR CARCINOMA PROGRESSION. HEPATOCELLULAR CARCINOMA (HCC) IS ONE TYPE OF CANCERS WHOSE CARCINOGENESIS AND PROGRESSION ARE CLOSELY RELATED TO CHRONIC INFLAMMATION. IDENTIFYING THE MOLECULAR MECHANISMS FOR INFLAMMATION-RELATED HCC PROGRESSION WILL CONTRIBUTE TO IMPROVE THE EFFICACY OF CURRENT THERAPEUTICS FOR HCC PATIENTS. MANY KINDS OF EPIGENETIC FACTORS, INCLUDING LONG NON-CODING RNAS (LNCRNAS), HAVE BEEN DISCOVERED TO BE IMPORTANT IN HCC GROWTH AND METASTASIS. HOWEVER, HOW THE LNCRNAS PROMOTE HCC PROGRESSION AND WHAT'S THE APPLICATION OF LNCRNA SILENCING IN VIVO IN SUPPRESSING HCC REMAIN TO BE FURTHER INVESTIGATED. HERE, WE FOUND THAT LNCRNA METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT1 (MALAT1) WAS UPREGULATED IN HCC TUMOR TISSUES, AND KNOCKDOWN OF MALAT1 SUPPRESSED PROLIFERATION, CELL CYCLE AND INVASION OF HCC CELLS IN RESPONSE TO LIPOPOLYSACCHARIDE (LPS) STIMULATION. KNOCKDOWN OF MALAT1 SIGNIFICANTLY INHIBITED LPS-INDUCED PRO-INFLAMMATORY MEDIATORS IL-6 AND CXCL8 EXPRESSION IN HCC CELLS, WHICH COULD BE RESTORED BY OVEREXPRESSING MALAT1. MECHANISTICALLY, MALAT1 RECRUITED BRAHMA-RELATED GENE 1 (BRG1), A CATALYTIC SUBUNIT OF CHROMATIN REMODELING COMPLEX SWITCHING/SUCROSE NON-FERMENTABLE (SWI/SNF), TO THE PROMOTER REGION OF IL-6 AND CXCL8, AND THUS FACILITATED NF-KAPPAB TO INDUCE THE EXPRESSION OF THESE INFLAMMATORY FACTORS. IMPORTANTLY, IN VIVO SILENCING OF MALAT1 IN HCC TISSUES INHIBITED GROWTH OF HCC XENOGRAFTS, AND ALSO SUPPRESSED THE EXPRESSION OF PRO-INFLAMMATORY FACTORS IN HCC TISSUES ACCORDINGLY. OUR RESULTS DEMONSTRATE THAT MALAT1 PROMOTES HCC PROGRESSION BY BINDING BRG1 TO EPIGENETICALLY ENHANCE INFLAMMATORY RESPONSE IN HCC TISSUES, AND SILENCING OF MALAT1 MAY BE A POTENTIAL APPROACH TO THE TREATMENT OF HCC. 2019 18 2430 30 EPIGENETIC SILENCING OF MIR-210 INCREASES THE PROLIFERATION OF GASTRIC EPITHELIUM DURING CHRONIC HELICOBACTER PYLORI INFECTION. PERSISTENT COLONIZATION OF THE GASTRIC MUCOSA BY HELICOBACTER PYLORI (HP) ELICITS CHRONIC INFLAMMATION AND ABERRANT EPITHELIAL CELL PROLIFERATION, WHICH INCREASES THE RISK OF GASTRIC CANCER. HERE WE EXAMINE THE ABILITY OF MICRORNAS TO MODULATE GASTRIC CELL PROLIFERATION IN RESPONSE TO PERSISTENT HP INFECTION AND FIND THAT EPIGENETIC SILENCING OF MIR-210 PLAYS A KEY ROLE IN GASTRIC DISEASE PROGRESSION. IMPORTANTLY, DNA METHYLATION OF THE MIR-210 GENE IS INCREASED IN HP-POSITIVE HUMAN GASTRIC BIOPSIES AS COMPARED WITH HP-NEGATIVE CONTROLS. MOREOVER, SILENCING OF MIR-210 IN GASTRIC EPITHELIAL CELLS PROMOTES PROLIFERATION. WE IDENTIFY STMN1 AND DIMT1 AS MIR-210 TARGET GENES AND DEMONSTRATE THAT INHIBITION OF MIR-210 EXPRESSION AUGMENTS CELL PROLIFERATION BY ACTIVATING STMN1 AND DIMT1. TOGETHER, OUR RESULTS HIGHLIGHT INFLAMMATION-INDUCED EPIGENETIC SILENCING OF MIR-210 AS A MECHANISM OF INDUCTION OF CHRONIC GASTRIC DISEASES, INCLUDING CANCER, DURING HP INFECTION. 2014 19 5479 39 RESVERATROL ATTENUATES CIGARETTE SMOKE EXTRACT INDUCED CELLULAR SENESCENCE IN HUMAN AIRWAY EPITHELIAL CELLS BY REGULATING THE MIR-34A/SIRT1/NF-KAPPAB PATHWAY. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS CHARACTERIZED BY ACCELERATED LUNG AGING. SMOKING IS THE CRITICAL RISK FACTOR FOR COPD. CELLULAR SENESCENCE OF AIRWAY EPITHELIAL CELLS IS THE CYTOLOGICAL BASIS OF ACCELERATED LUNG AGING IN COPD, AND THE REGULATION OF MICRORNAS (MIRNAS) IS THE CENTRAL EPIGENETIC MECHANISM OF CELLULAR SENESCENCE. RESVERATROL (RES) IS A POLYPHENOL WITH ANTI-AGING PROPERTIES. THIS STUDY INVESTIGATED WHETHER RES ATTENUATES CIGARETTE SMOKE EXTRACT (CSE)-INDUCED CELLULAR SENESCENCE IN HUMAN AIRWAY EPITHELIAL CELLS (BEAS-2B) THROUGH THE MIR-34A/SIRT1/NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) PATHWAY. BEAS-2B CELLS WERE TREATED WITH RES, CSE AND TRANSFECTED WITH MIR-34A-5P MIMICS. CELLULAR SENESCENCE WAS EVALUATED BY SENESCENCE -RELATED BETA-GALACTOSIDASE (SA-BETA-GAL) STAINING AND EXPRESSION OF SENESCENCE-RELATED GENES (P16, P21, AND P53). THE EXPRESSIONS OF MIR-34A-5P, SIRT1, AND NF-KAPPAB P65 WERE EXAMINED USING QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION AND WESTERN BLOTTING. THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) WERE ASSESSED BY ENZYME-LINKED IMMUNOSORBENT ASSAY. THE BINDING BETWEEN MIR-34A-5P AND SIRT1 WAS CONFIRMED BY DUAL-LUCIFERASE REPORTER ASSAY. THE RESULTS SHOWED THAT CSE DOSE-DEPENDENTLY DECREASED CELL VIABILITY AND ELEVATED CELLULAR SENESCENCE, CHARACTERIZED BY INCREASED SA-BETA-GAL STAINING AND SENESCENCE-RELATED GENE EXPRESSIONS (P16, P21, AND P53). FURTHER, CSE DOSE-DEPENDENTLY INCREASED THE EXPRESSION OF MIR-34A-5P AND SASP CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) IN BEAS-2B CELLS. PRETREATMENT WITH RES INHIBITED CSE-INDUCED CELLULAR SENESCENCE AND SECRETION OF SASP CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) IN A DOSE-DEPENDENT MANNER. MOREOVER, RES REVERSED THE CSE-INDUCED DOWN-REGULATION OF SIRT1 AND UP-REGULATION OF MIR-34A-5P AND NF-KAPPAB P65. SIRT1 IS A TARGET OF MIR-34A-5P. OVEREXPRESSION OF MIR-34A-5P VIA TRANSFECTION WITH MIR-34A-5P MIMIC IN BEAS-2B CELLS ATTENUATED THE INHIBITORY EFFECT OF RES ON CELLULAR SENESCENCE, ACCOMPANIED BY REVERSING THE EXPRESSION OF SIRT1 AND NF-KAPPAB P65. IN CONCLUSION, RES ATTENUATED CSE-INDUCED CELLULAR SENESCENCE IN BEAS-2B CELLS BY REGULATING THE MIR-34A/SIRT1/NF-KAPPAB PATHWAY, WHICH MAY PROVIDE A NEW APPROACH FOR COPD TREATMENT. 2022 20 4873 39 OVER-EXPRESSION OF PROTHYMOSIN-ALPHA ANTAGONIZES TGFBETA SIGNALLING TO PROMOTE THE DEVELOPMENT OF EMPHYSEMA. EMPHYSEMA, A MAJOR CONSEQUENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), IS CHARACTERIZED BY THE PERMANENT AIRFLOW RESTRICTION RESULTING FROM ENLARGEMENT OF ALVEOLAR AIRSPACE AND LOSS OF LUNG ELASTICITY. TRANSFORMING GROWTH FACTOR-BETA (TGFBETA) SIGNALLING REGULATES THE BALANCE OF MATRIX METALLOPROTEINASE (MMP)/TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE (TIMP) TO CONTROL MATRIX HOMEOSTASIS. PATIENTS WITH COPD HAVE DYSREGULATED TGFBETA SIGNALLING AND REDUCED HISTONE DEACETYLASE (HDAC) ACTIVITY THROUGH EPIGENETIC UP-REGULATION OF HISTONE ACETYLATION IN THE PROMOTERS OF PRO-INFLAMMATORY GENES. HOWEVER, THE POTENTIAL LINK BETWEEN DECREASED HDAC ACTIVITY AND DYSREGULATED TGFBETA SIGNALLING IN EMPHYSEMA PATHOGENESIS REMAINS TO BE DETERMINED. PROTHYMOSIN ALPHA (PROT), A HIGHLY CONSERVED ACIDIC NUCLEAR PROTEIN, PLAYS A ROLE IN THE ACETYLATION OF HISTONE AND NON-HISTONE PROTEINS. THE AIM OF THIS STUDY WAS TO TEST THE HYPOTHESIS THAT PROT INHIBITS TGFBETA-SMAD SIGNALLING THROUGH SMAD7, THEREBY CONTRIBUTING TO EMPHYSEMA PATHOGENESIS. WE SHOW THAT PROT ENHANCES SMAD7 ACETYLATION BY DECREASING ITS ASSOCIATION WITH HDAC AND THEREBY DOWN-REGULATES TGFBETA-SMAD SIGNALLING. PROT CAUSED AN IMBALANCE BETWEEN MMP AND TIMP THROUGH ACETYLATED SMAD7 IN FAVOUR OF MMP EXPRESSION. IN ADDITION TO INTERFERING WITH R-SMAD ACTIVATION AND TARGETING RECEPTORS FOR DEGRADATION IN THE CYTOPLASM, ACETYLATED SMAD7 POTENTIATED BY PROT COMPETITIVELY ANTAGONIZED BINDING OF THE PSMAD2/3-SMAD4 COMPLEX TO THE TIMP-3 PROMOTER, RESULTING IN REDUCED TIMP-3 EXPRESSION. THESE EFFECTS WERE DETECTED IN PROT-OVER-EXPRESSING CELLS, LUNGS OF PROT TRANSGENIC MICE DISPLAYING AN EMPHYSEMA PHENOTYPE AND IN EMPHYSEMA PATIENTS. IMPORTANTLY, INCREASED SMAD7 AND REDUCED TIMP-3 WERE FOUND IN THE LUNGS OF EMPHYSEMA PATIENTS AND MICE WITH CIGARETTE SMOKE EXTRACT (CSE)-INDUCED EMPHYSEMA. SUCH EFFECTS COULD BE ABROGATED BY SILENCING ENDOGENOUS PROT EXPRESSION. COLLECTIVELY, OUR RESULTS UNCOVER ACETYLATED SMAD7 REGULATED BY PROT AS AN IMPORTANT DETERMINANT IN DYSREGULATED TGFBETA SIGNALLING THAT CONTRIBUTES TO EMPHYSEMA PATHOGENESIS. 2016